News
Press releases, research, events, and updates from the team building clinical-trial infrastructure for health systems.
Expert-Validated: Lind's AI Matches Clinical Coordinators 94% of the Time (JCO Oncology Practice)
A new peer-reviewed study in JCO Oncology Practice validated Lind's AI trial-matching system (TRIAGE) against expert clinical research coordinators using real-world EHR data. Across 1,770 adjudicated criteria, TRIAGE reached 94.2% agreement, and at its high-sensitivity threshold identified eligible patients with 98.7% sensitivity and 97.6% specificity surfacing missed enrollment opportunities in minutes. Conducted at Atrium Health's NCI-designated cancer center across 168 oncology trials and 806 patients, the study found TRIAGE accurately determines trial eligibility from complex, longitudinal records, supporting clinician review rather than replacing it. Prospective implementation studies are underway.
Read on ascopubs.org
Advocate Health Partners with AI Startup to Connect More Patients with Cancer to Clinical Trials
Advocate Health, the third largest health system in the United States, is reinforcing its role as a national leader in oncology care and artificial intelligence innovations by partnering with Lind to help connect more cancer patients to potentially life-saving clinical trials. The partnership will begin in oncology and expand to other diseases as Advocate moves to advance their research goals across therapeutic areas.
Read on newswise.comLind Asia launched (joint venture with PREMIA) to expand clinical trial matching to APAC Countries
Lind and Precision Medicine Asia (PREMIA) formed Lind Asia, a JV to bring AI-powered trial screening to Taiwan, Japan, South Korea, Singapore, and Australia. Lind Asia is the exclusive regional partner for Lind's platform; three pillars: AI patient identification, research-ready site network, integrated molecular profiling.
Read on manilatimes.net
Lind and Advocate Health take the stage at HLTH 2025 (Las Vegas)
Lind and Advocate Health appeared together at HLTH 2025 in Las Vegas to discuss how clinician-guided AI is transforming clinical trial access. They highlighted early results from one of the nation's largest health systems embedding automated trial screening directly into the EHR.
Read the story
Shrujal Baxi, MD, MPH Joins Lind as Chief Medical Officer
Lind has appointed Shrujal Baxi, MD, MPH, as Chief Medical Officer. A medical oncologist and real-world evidence leader bringing health technology and clinical trial experience to the team having worked at Flatiron Health, Verana and Iterative Scopes. Baxi, a practicing physician will guide Lind's clinical strategy as it scales AI-enabled trial screening and operational solutions across health systems.
Read on businesswire.comLind Partners with Investigators at NCI on AACR Abstract: Structuring the unstructured: How protocol quality and precision drive clinical trial completion
At the AACR Annual Meeting 2025, Lind presented Abstract LB373, applying large language models and machine learning to 12,096 oncology trials. The framework predicted trial completion with ~81% accuracy and showed that simpler, guideline-aligned protocols with fewer restrictive eligibility criteria enroll and complete more successfully.
Read the story
Lind Returns to the CancerX Moffitt Innovation Summit as Accelerator Alumni
Lind returned to the CancerX Accelerator Moffitt Innovation Summit in 2025, joining an Alumni Fireside Chat to share how an inaugural-cohort startup has scaled into enterprise health-system contracts and where clinician-guided AI trial screening goes next.
Read the story
Oggie Nikolic, Lind co-founder, featured on Healio
Founder & CEO Oggie Nikolic featured in a Healio video discussing the CancerX experience and the power of Lind's platform. He focuses on the opportunities generated through participation in this incubator.
Read on healio.comLind announces Advisory Board
Lind announced the formation of its Advisory Board, bringing together leaders across oncology, clinical research, health-system operations, and AI to guide the company as it scales clinician-guided trial screening across health systems.
Read the story
Lind selected for Creative Destruction Lab's Computational Health Program
Lind has been selected for the Creative Destruction Lab (CDL) Computational Health program, based at the University of Washington's Foster School of Business in Seattle. The program pairs early-stage health technology companies with experienced mentors from industry and academia over a nine-month structured program.
Read the story We Graduated from the Inaugural CancerX Accelerator. Here's What We Learned
Lind is now a graduate of the inaugural CancerX Accelerator. In a founder reflection, CEO Oggie Nikolic shares what working alongside Champion health systems taught the team and why EHR-embedded, disease-agnostic screening that adds zero work for coordinators became non-negotiable in Lind's product design.
Read the storyLind at ASCO 2025: A Comprehensive LLM Platform for Clinical Trial Screening
Presented at the 2025 ASCO Annual Meeting, this study introduces Lind's large language model platform for cancer trial screening, designed to prioritize and evaluate patient-trial matches and streamline human review. It directly targets a core bottleneck in oncology research: 80% of trials fail to meet enrollment timelines, largely due to inefficient patient-trial matching.
Read on ascopubs.org Lind Selected for Inaugural CancerX Accelerator Cohort
Lind was selected as one of 16 startups in the inaugural cohort of the CancerX Accelerator — the public-private startup accelerator under the White House Cancer Moonshot, co-hosted by Moffitt Cancer Center and the Digital Medicine Society (DiMe) in collaboration with the Office of the National Coordinator for Health IT (ONC) and the Office of the Assistant Secretary for Health (OASH). The cohort gave Lind access to federal partners, mentors, and health-system collaborators to validate its trial-screening platform.
Read on prnewswire.comLind Raises Seed Round to Build Intelligent Clinical Trial Infrastructure
Lind raised $5.5M in seed funding led by 8VC, Abstract Ventures, and Correlation Ventures to build the first trial, screening platform designed for health systems, not sponsors. Lind screens every patient against every open study nightly, surfacing EHR-native matches with evidence already mapped to eligibility criteria.
Read the storyNo stories match your search.